MedicalResearch.com - Latest news, interviews, and insights into medical research, health and wellness, fitness and addiction.
Author Interviews, Cannabis, JAMA, Opiods / 13.11.2025

MedicalResearch.com Interview with: Victoria Bethel, MSN Department of Public Administration and Policy University of Georgia, Athens   MedicalResearch.com: What is the background for this study? Response: From the same pool of commercially insured patients, we found that cannabis dispensary openings were associated with reduced opioid prescribing among patients with non-cancer pain. For this study, we examined whether cannabis dispensary openings were also associated with reduced opioid prescribing among commercially insured patients who do have a cancer diagnosis. Similar to patients without cancer, we estimated reductions in opioid prescribing after medical and recreational cannabis dispensaries open. These findings may suggest that patients who experience cancer pain are able to manage their pain with cannabis instead of requiring opioids, although we cannot directly observe substitution. (more…)
Addiction, addiction-treatment, Author Interviews, Opiods / 13.10.2025

MedicalResearch.com Interview with: Krisha S. Patel Center For Pharmacy Innovation and Outcomes Geisinger College Health Sciences Scranton, PA MedicalResearch.com: What is the background for this study? Response: Hydromorphone is a powerful opioid medication approved for treating moderate to severe acute pain, as well as chronic pain that doesn’t respond to other treatments. One brand name is Dilaudid. It is much more potent than morphine, about 5 to 10 times stronger, and crosses the blood-brain barrier more efficiently. Hydromorphone comes in several forms, including oral powders, solutions, immediate- and extended-release tablets, and injectable options like intravenous, intramuscular, and subcutaneous. Like morphine, hydromorphone primarily targets the mu-opioid receptors, with some activity at delta receptors. Its higher fat solubility gives it a faster onset of action than morphine, though not as rapid as fentanyl. Due to its potency and risk for misuse and overdose, hydromorphone is typically prescribed only when other pain management options have failed. According to the RADARS StreetRx Program, in 2023, the black-market value of a 1 mg immediate-release tablet was about $15,000 annually, with extended-release tablets reaching $62,000 for a full-years supply. While previous studies have explored regional differences in the use of opioids like morphine, oxycodone, and codeine, hydromorphone has not been examined. This study aims to fill that gap by analyzing state-level and temporal trends in hydromorphone use across the US from 2010 to 2023. It draws on data from three major sources: the Drug Enforcement Administration’s Automated Reports and Consolidated Orders System (ARCOS), Medicaid, and Medicare Part D. By comparing these datasets, this report also explores how hydromorphone distribution and prescribing patterns have evolved over time. (more…)
Author Interviews, Opiods / 18.09.2025

PainRelief.com Interview with: Shravani Durbhakula, MD, MPH, MBA Associate Professor of Anesthesiology, Division of Pain Medicine Vanderbilt University School of Medicine Medical Director, Comprehensive Pain Service Vanderbilt University Medical Center PainRelief.com: What is the background for this study? Response: Our study highlights the rapid rise of nitazenes—extremely potent and dangerous synthetic opioids—silently driving the current overdose crisis. Developed in the 1950s by a pharmaceutical company and never approved for clinical use, nitazenes are up to 20 times more potent than fentanyl and are undetectable with standard drug tests available in emergency rooms. These opioids are often mixed into counterfeit pills or other street drugs, posing an unseen threat. Furthermore, nitazenes interact with opioid receptors in a unique way, increasing overdose risk, heightening respiratory depression, and accelerating tolerance development, which makes them even more dangerous for users. (more…)
Addiction, addiction-treatment, Opiods / 23.07.2025

MedicalResearch.com Interview with: Maria Gikoska, MBS Geisinger College of Health Sciences Scranton, PA 18509 MedicalResearch.com: What is the background for this study? Response: Opioid use disorder (OUD) is a chronic condition that continues to substantially impact public health in the United States (U.S.), with approximately 5.7 million people affected in 2023. Buprenorphine, a partial mu-opioid receptor agonist, is widely used for treating OUD due to its safety profile, high treatment retention, and effectiveness in reducing opioid-related mortality. Since its approval in 2002, its use has increased, though not uniformly across states. Factors such as the now- eliminated X-waiver, telemedicine expansions during the COVID-19 pandemic, and differing state level policies have influenced buprenorphine access. The study sought to evaluate national and state-level pattern in buprenorphine distribution from 2019-2023 to understand disparities and inform public health interventions. (more…)
Addiction, addiction-treatment, Opiods / 07.10.2024

The opioid crisis has left an indelible mark on society, affecting millions of individuals and families across the globe. While the physical and psychological tolls of opioid addiction are well-documented, another profound challenge often lurks in the shadows: the stigma surrounding opioid use disorder (OUD). Stigma, which manifests as judgment, discrimination, and negative perceptions, can be one of the most significant barriers to seeking treatment and achieving recovery. Overcoming this stigma is crucial for creating a supportive environment that encourages individuals to pursue and sustain their recovery journey.

Understanding Stigma in Opioid Addiction

Stigma can be defined as a set of negative beliefs or attitudes directed toward a particular group of people. In the context of opioid addiction, it often revolves around misconceptions that individuals suffering from OUD are morally flawed, weak-willed, or choosing to engage in substance use. These harmful stereotypes perpetuate a culture of shame and silence, discouraging people from seeking help for fear of being judged or ostracized. The stigma around opioid addiction is fueled by various factors. Historically, addiction was viewed as a moral failing or criminal behavior rather than a medical condition. This perception persists, even though extensive research has shown that opioid addiction is a chronic brain disease influenced by genetics, environment, and mental health. Additionally, sensationalized media coverage of drug-related crimes and overdose deaths further reinforces negative stereotypes, casting individuals with OUD in a criminalized light. (more…)
Addiction, Author Interviews, Opiods / 03.07.2024

MedicalResearch.com Interview with: Elena Stains Elena Stains Medical Student Department of Medical Education Geisinger Commonwealth School of Medicine Scranton, PA   MedicalResearch.com: What is the background for this study? Response: Opioid use has been an increasing problem since the early 2000s in the United States (US) with a surge around 2010. Twenty-five percent of those having abused pain relievers in 2013 and 2014 got those drugs from physicians1. Physicians are particularly well-known for fueling the opioid crisis in Florida in the 2000s. Of the United States’ top 100 opioid prescribing physicians in 2010, an astounding 98 were prescribing in Florida2. Florida taking the main stage of the opioid crisis can be attributed to several factors, including ability of physicians to dispense opioids directly from their offices to patients (i.e. without pharmacists) and the presence of many infamous “pill mills” in the state3–6. The researchers at Geisinger Commonwealth School of Medicine aimed to analyze the amount of hydrocodone (including brand names of Vicodin and Lortab) and oxycodone (OxyContin and Percocet) distributed in Florida from 2006 to 2021, paying close attention to the peak year of the opioid crisis, 2010. The team used the Washington Post and the US Drug Enforcement Administration’s Automation of Reports and Consolidated Orders System (ARCOS) databases to compile this compelling information. (more…)
Dental Research, Opiods / 31.05.2024

Key Takeaways
  • Prescription medications, like Suboxone, may have unexpected side effects, including dental health issues.
  • It's crucial for everyone, particularly those on prolonged medication, to prioritize proper oral care.
  • Familiarizing yourself with medication side effects empowers you to take preemptive steps to safeguard your well-being.
  • Consistent dental examinations and embracing a healthy lifestyle can help alleviate certain medication-related risks.
Introduction to Prescription Medications and Dental Health Prescription medications can be life-saving, but they often come with side effects that patients may not fully understand. One such medication is Suboxone, a vital tool in treating opioid addiction. While Suboxone is effective for its intended purpose, it has been linked to significant dental health issues, including tooth decay. Recent reports and studies have highlighted the concern over a suboxone lawsuit tooth decay issue, emphasizing the need for awareness and preventive measures. Without the proper knowledge, patients might find themselves facing unexpected health challenges. (more…)
Author Interviews, Opiods, Pain Research / 29.03.2024

MedicalResearch.com Interview with: Jay P. Solgama Medical Student Department of Medical Education Geisinger Commonwealth School of Medicine Scranton PA   MedicalResearch.com: What is the background for this study? Response: The opioid crisis in the United States continues to escalate, with opioid-related deaths increasing by over 800% since 2000. Prescription opioids, particularly oxycodone, have been a contributor to this crisis, with substantial variations in their distribution observed across different states [1,2,3]. Against this backdrop, the study conducted by researchers from the Geisinger Commonwealth School of Medicine aimed to characterize the distribution of oxycodone across US states from 2000 to 2021. By analyzing data from the Drug Enforcement Administration’s comprehensive Automation of Reports and Consolidated Orders System (ARCOS) and the Centers for Disease Control and Prevention Wide-ranging ONline Data for Epidemiologic Research (WONDER) databases, the study sought to identify trends and patterns in oxycodone distribution and their potential implications for opioid-related deaths [4,5]. (more…)
Addiction, Author Interviews, Gastrointestinal Disease, Opiods / 03.02.2024

MedicalResearch.com Interview with: Joshua D. Madera, MD Department of Medical Education Geisinger Commonwealth School of Medicine Scranton PA What is the background for this study? Response: The US population continues to be drastically impacted by the opioid epidemic, with opioid-related deaths significantly increased compared to European countries. While prescription opioid distribution has gradually declined since its peak in 2011 [1], the rate of opioid prescriptions remains increased compared to 2000. Furthermore, there is considerable interstate variability in opioid distribution across the US. Identifying patterns in this variability may guide public health efforts to reduce opioid-related harms. Therefore, the primary objective of this study [2] from Geisinger Commonwealth School of Medicine was to explore variations in production quotas and state-level distribution of ten prescription opioids between 2010 and 2019. (more…)
Author Interviews, Opiods, Pain Research / 07.10.2023

MedicalResearch.com Interview with: Leana Pande Touro College of Osteopathic Medicine MedicalResearch.com: What is the background for this study? Response: Buprenorphine is not a new drug. It was developed in the 1960s with the intent of providing the benefits of opioids, without the addictive side effects. Unlike many prescription opioids,1 use of this Schedule III drug is increasing.2 It is often characterized as a partial agonist at the mu-opioid receptor (Figure-Right). Buprenorphine is available in many routes of administration and also with (brand name Suboxone) or without naloxone. Buprenorphine is a first-line pharmacotherapy for pregnant women with OUD.3 This review was completed in order for the benefits, and risks, of buprenorphine to be more fully appreciated and inform utilization for both opioid use disorder (OUD) and the treatment of pain. (more…)
Anesthesiology, Author Interviews, Cannabis, JAMA, Opiods, Surgical Research, University Texas / 10.07.2023

MedicalResearch.com Interview with: Paul Potnuru, MD Assistant Professor Anesthesiology, Critical Care and Pain Medicine The John P. and Kathrine G. McGovern Medical School The University of Texas Health Science Center at Houston UTHealth MedicalResearch.com: What is the background for this study? Response: The use of cannabis is on the rise in the United States, as it becomes increasingly legally accepted and is viewed as harmless. Furthermore, the potency of cannabis is steadily increasing over time. There is some evidence from previous studies that compared to non-users, cannabis users require more anesthetics, have higher pain after surgery that requires more opioids, and have an increased risk of postoperative nausea and vomiting. Given this context of increased usage and potential risks during surgery, we conducted a study to examine the impact of cannabis use on patients undergoing surgery. (more…)
Addiction, Author Interviews, COVID -19 Coronavirus, Opiods / 07.02.2023

MedicalResearch.com Interview with: Brian Piper, PhD MS Assistant Professor of Neuroscience Center for Pharmacy Innovation & Outcomes Geisinger School of Graduate Education MedicalResearch.com: What is the background for this study? Response: Methadone is an evidence-based treatment of opioid use disorder (OUD) and pain. However, this Schedule II opioid can also cause respiratory depression, which can result in lethality. The need for supervised administration is a long-standing source of frustration in the U.S. for many opioid use disorder (OUD) methadone patients. However, there was an accommodation in early 2020 thanks to the COVID-19 pandemic. This involved extending the take-home supply to up to 28-days for stable patients and 14 days for less stable patients. Prior research found that the implementation of supervised administration in England greatly reduced methadone overdoses [1]. The primary objective of this study [2] from Geisinger Commonwealth School of Medicine was to determine if the relaxation of the take-home rules resulted in more methadone overdoses. (more…)
Addiction, Author Interviews, Opiods / 29.12.2022

MedicalResearch.com Interview with: Alden MiletoAlden Mileto, BA Department of Medical Education Geisinger Commonwealth School of Medicine Scranton, PA MedicalResearch.com: What is the background for this study? Response: The drug buprenorphine is a partial opioid agonist, originally developed in the 1960s as an alternative to the stronger full opioid mu receptor agonists like morphine. Today, the drug is sometimes used for pain, but is more often used as a treatment for Opioid Use Disorder (OUD). Since the 2002 federal approval for buprenorphine use in treatment of OUD, there has been an increase in buprenorphine prescription across all states. However recent studies have showed a disproportionate increase in buprenorphine prescriptions to rural/ less populated areas in comparison to urban/densely populated areas. The objective of this study [1] was to analyze the trends in buprenorphine distribution, overall and by three-digit zip codes, in Pennsylvania from 2010-2020. (more…)
Addiction, Author Interviews, Opiods / 07.06.2022

MedicalResearch.com Interview with: Colleen G. Jordan, MBS Department of Medical Education Geisinger Commonwealth School of Medicine MedicalResearch.com: What is the background for this study? Response: Opioid addiction and misuse remain a prevalent issue in the United States (U.S.). There have been more than one-million drug overdoses in the U.S. since 1999 [1], largely driven by opioids, which exacerbate the strain on resources in hospitals, treatment centers, first responders, patients, and their families. The existing pharmacotherapies for opioid use disorder (OUD) are not working. Naloxone is a competitive mu opioid receptor antagonist used to reverse respiratory and CNS depression in those experiencing an opioid overdose but requires further dosing to prevent subsequent overdose. Naltrexone is a competitive mu opioid receptor antagonist, and has extended-release formulations intended to reduce relapse and promote adherence, yet patient noncompliance and retention continue to be limiting factors. Methadone is commonly used to treat opioid addiction as a replacement for illicit opiates but is itself an addictive substance which can result in overdoses [2] and can lead to withdrawal if not closely monitored by a licensed professional. Buprenorphine is currently used to treat opioid use disorder (OUD), and while it reduces illicit drug use, it is less effective than methadone for retaining patients in treatment. For these reasons, there is an urgent need for new opioid misuse interventions. The objectives of this study [3] were to understand the implications of OUD and overdose treatments and determine the strengths and shortcomings of current treatments in comparison with the novel drug candidate methocinnamox (MCAM). These were completed through an extensive literature review into the history of the opioid epidemic in the United States, opioid receptors in the brain, current pharmacological treatments, and the pharmacological properties of MCAM. (more…)
Addiction, Author Interviews, Opiods, PLoS / 04.02.2022

MedicalResearch.com Interview with: Dr. Laurence Moss MD, PhD candidate Centre for Human Drug Research (CHDR) Department of Anesthesiology Leiden University Medical Centre (LUMC) Geert Jan Groeneveld​, MD, PhD Neurologist | Clinical Pharmacologist | Professor of Clinical Neuropharmacology CMO/CSO Centre for Human Drug Research Leiden, The Netherlands  MedicalResearch.com:  What is the background for this study?    Response: Opioid use disorder (OUD) is a major source of morbidity and mortality, and the opioid epidemic in the Unites States (but increasingly in Europe also) has been well documented and reported on by the media. The alarming rise in opioid related mortality is largely driven by the increasing use of fentanyl and fentanyl analogues, often surreptitiously mixed with heroin or other drugs such as psychostimulants or prescribed opioids. Opioid-induced respiratory depression in particular is a leading cause of opioid-related fatalities. Buprenorphine has been proven as an effective medication for the treatment of OUD. Buprenorphine is a semi-synthetic partial agonist for the opioid receptor that firmly binds to these receptors and displays only partial respiratory depressive effects, meaning it does not cause the complete cessation of breathing as is the case with other potent opioids such as fentanyl. Due to its firm receptor binding, we hypothesized that at sufficient buprenorphine receptor occupancy, the effect of fentanyl on respiration would be limited, even at high fentanyl doses. This study aimed to provide proof of principle for this hypothesis, and demonstrate whether buprenorphine could reduce fentanyl-induced respiratory depression. (more…)
Author Interviews, CDC, Opiods / 28.12.2021

MedicalResearch.com Interview with: Julie O’Donnell, PhD MPH Division of Overdose Prevention National Center for Injury Prevention and Control CDC National Network of Public Health Institutes New Orleans, Louisiana MedicalResearch.com: What is the background for this study? Response: The estimated number of drug overdose deaths in the US surpassed 100,000 over a 12-month period for the first time during May 2020-April 2021, driven by the involvement of synthetic opioids other than methadone (mainly illicitly manufactured fentanyl (IMF)), according to data from the National Vital Statistics System. The State Unintentional Drug Overdose Reporting System (SUDORS) is a CDC-funded surveillance program that has collected detailed data on unintentional and undetermined intent drug overdose deaths since 2016 from death certificates, medical examiner and coroner reports, and full postmortem toxicology reports. SUDORS data allow for the analysis specifically of deaths involving fentanyl (rather than the larger category of synthetic opioids), and contain information about decedent demographics and other characteristics, as well as circumstances surrounding the overdose that might help inform prevention. (more…)
Author Interviews, JAMA, Opiods, University of Pennsylvania / 14.12.2021

MedicalResearch.com Interview with: Ashish Thakrar, MD Internal Medicine & Addiction Medicine National Clinician Scholars Program University of Pennsylvania MedicalResearch.com: What is the background for this study? Response: About 1.8 million Americans are currently incarcerated, more than any other country in the world per capita. Of those 1.8 million, about 1 in 7 suffers from opioid addiction, putting them at high risk of overdose and death, particularly in the weeks following release. Opioid use disorder is a treatable condition, particularly with the medications buprenorphine or methadone, but historically, prisons and jails have not offered treatment. Over the past five years, a few states and municipalities have enacted policies to provide access for OUD treatment. We examined whether these policies were actually improving access to treatment.  (more…)
Anesthesiology, Author Interviews, Brigham & Women's - Harvard, Opiods, Surgical Research / 21.09.2021

MedicalResearch.com Interview with: Andres Zorrilla Vaca, MD Resident Physician Brigham and Women’s Hospital Boston, Massachusetts  MedicalResearch.com: What is the background for this study? Response: The background for this study was Enhanced Recovery After Surgery, also known as ERAS protocols. They basically consisted of a bundle of interventions that are performed preoperatively, intraoperatively and postoperatively with the aim of enhancing patient recovery and reducing complications. This protocol in our institution started with a thorough preoperative counseling which includes, smoking cessation, pain and analgesia education, ERAS program expectations, pulmonary rehabilitation based on pulmonary function tests and incentive spirometry. On the day of surgery, prolonged fasting is avoided and a carbohydrate loading is given orally 2 hours before surgery. Our protocol also included a standardized multimodal analgesic regimen consisting of tramadol ER 300mg p.o. and gabapentin 300mg p.o., intraoperative acetaminophen 1gm i.v., posterior intercostal nerve blockade with liposomal bupivacaine 266mg prior to incision, intraoperative 30mg ketorolac upon wound closure and scheduled postoperative acetaminophen 1g p.o. q 6hrs and ketorolac 15mg i.v. q 6 hrs, as well as additonal interventions recommended by ERAS Society Guidelines. As a general rule, preoperative sedatives (midazolam) are avoided as premedication and prophylaxis against nausea and vomiting (ondansetron, dexamethasone and scopolamine) is administered. Patients are kept euvolemic by using validated goal-directed fluid therapy algorithms (stroke volume variation and cardiac output) and normothermia is maintained throughout the procedure. (more…)
Addiction, Author Interviews, Opiods, Race/Ethnic Diversity / 10.09.2021

John A. Furst BS Geisinger Commonwealth School of Medicine MedicalResearch.com: What is the background for this study? Response: Methadone is an evidence-based pharmacotherapy for opioid detoxification, maintenance therapy, and pain management. However, accessibility of this treatment remains variable across much of the country. Methadone for the treatment of opioid use disorder (OUD) is exclusively provided by federally regulated opioid treatment programs (OTPs) and has provoked significant community-based and legal controversy regarding its role in the management of this condition. This has created disparities related to the distribution and access of methadone throughout the United States (U.S.). The goal of this study1 was to highlight the most recent pharmacoepidemiologic trends associated with methadone in the face of unique restrictions at the local, state, and federal levels. (more…)
Author Interviews, Opiods / 27.06.2021

http://www.indivior.com/This study and abstract presentation evaluated opioid withdrawal symptoms, safety and tolerability of initiating SUBLOCADE 300 mg one hour after administering a single dose of 4 mg transmucosal (sublingual) buprenorphine (BUP-TM). 26 participants received BUP-TM, 24 follow by  SUBLOCADE injection, and 20 completed the study. Participants were evaluated for opioid withdrawal symptoms as well as safety and tolerability of SUBLOCADE 300 mg. (more…)
Author Interviews, Opiods / 25.06.2021

MedicalResearch.com Interview with: John Boyle, BS Department of Medical Education Geisinger Commonwealth School of Medicine MedicalResearch.com: What is the background for this study? Response:  Meperidine is an opioid analgesic which has been approved for use since the 1940s for moderate to severe pain. During the 1990s, concerns about adverse effects (e.g., serotonin syndrome) and CYP450 drug interactions (e.g., 3A4 inhibition of other metabolism of other common medications) were raised and by 2003 it was removed from the WHO’s List of Essential Medicines. Despite increased awareness of adverse effects, meperidine is still used in the United States. It was the goal of this study1 to uncover pharmaepidemiological trends in its use. (more…)
Addiction, Author Interviews, Opiods / 24.06.2021

MedicalResearch.com: What is the background for this study? http://www.indivior.com/Response: Adults with moderate or severe opioid use disorder (OUD) were randomized to SUBLOCADE monthly injections or placebo and studied for 24 weeks. Participants receiving SUBLOCADE were given 2 monthly injections of 300 mg, followed by 4 monthly maintenance doses of 100 mg or 300 mg over the course of the study. (more…)
Author Interviews, Gastrointestinal Disease, Opiods / 24.05.2021

MedicalResearch.com Interview with: Frank Peacock, MD, FACEP, FACC Professor of Emergency Medicine, Associate Chair Research Director, Department of Emergency Medicine Baylor College of Medicine Houston, Texas MedicalResearch.com: What is the background for this study?  Response: Emergency medicine (EM) physicians, like myself, are always looking for ways to improve the patient experience. Often times, we will encounter a patient in the emergency department (ED) who is presenting with one of the most common side effects of opioids, which is opioid-induced constipation (OIC). OIC impacts 40-80% of patients on long-term opioid therapy[i],[ii] and may lead to emergency room visits which are associated with a significant burden on patients and the healthcare system. We wanted to compare the impact of treating OIC patients with FDA-approved prescription medications for OIC versus the impact of not treating OIC patients with an FDA-approved prescription medication for OIC in the ED setting to better understand the impact to overall ED costs and the length of stay for a hospitalized patient. (more…)
Author Interviews, BMJ, Cannabis, Opiods, Yale / 29.01.2021

MedicalResearch.com Interview with: Balázs Kovács PhD Associate Professor of Organizational Behavior Yale School of Management MedicalResearch.com: What is the background for this study? Response: Our study looks at the association between the prevalence of legal cannabis stores, called “dispensaries”, and opioid-related mortality rates in the U.S.  We find that higher cannabis dispensary counts are associated with reduced opioid-related mortality rates.   We find this relationship holds for both medical dispensaries, which only serve patients who have a state-approved medical card or doctor’s recommendation, as well as for recreational dispensaries, which sell to adults 21 years and older.  The statistical associations we find appears most pronounced with the class of opioids that includes fentanyl and its analogs.  (more…)
Author Interviews, Opiods, Pancreatic, PLoS / 08.01.2021

MedicalResearch.com Interview with: Faraz Bishehsari, MD, PhD Associate Professor of Medicine and Graduate College Director of the Translational Gastroenterology Unit Division of Digestive Diseases Rush University Medical Center MedicalResearch.com: What is the background for this study? Response: This study builds on recent population based studies where opium use was found to be possible risk factor for pancreatic cancer. Although opium use is not a common recreational habit in the United States, opioid use has been rising remarkably over the past decade. In fact, opioid misuse and overdose have evolved into a public health crisis here with increasing opioid prescription use and abuse over the past decade. (more…)
Author Interviews, Opiods / 20.12.2020

MedicalResearch.com Interview with: Brian J. Piper, PhD, MS Department of Medical Education Geisinger Commonwealth School of Medicine Scranton, PA 18510 MedicalResearch.com: What is the background for this study? Response: The US continues to be adversely impacted by an iatrogenic opioid epidemic. There have been increasing reports of “vet shopping” or diverting opioids from pets to their owners [2]. In humans, methadone is the number one prescription opioid when expressed in terms of morphine mg equivalents (MME) [3]. The goal of this study was to examine the changing pattern of opioid and other controlled substance use by veterinary teaching institutions.  (more…)
Addiction, Author Interviews, COVID -19 Coronavirus, JAMA, Opiods, UCLA / 03.12.2020

MedicalResearch.com Interview with: Joseph Friedman, MD/PhD student David Geffen School of Medicine UCLA MedicalResearch.com: What is the background for this study? Response: Numerous researchers, clinicians, officials, harm reduction agencies, and people who use drugs have sounded the alarm that the COVID-19 pandemic is exacerbating the United States overdose crisis. However, data sources typically used to track overdoses in the US often have long lags that impede timely monitoring and response. For example, the CDC released preliminary overdose figures for 2019 in July 2020, and even these numbers may change. As they are available in near real-time, emergency medical services (EMS) data have increasingly been used as a source of up-to-date information to monitor epidemiological shifts during the COVID-19 pandemic. In this study, we used data from the National EMS Information System (NEMSIS), a large registry of over 10,000 EMS agencies in 47 states that represented over 80% of all EMS activations nationally in 2020. We used the data to track shifts in overdose-related cardiac arrests observed by EMS.   (more…)
Author Interviews, Cannabis, Opiods / 22.06.2020

MedicalResearch.com Interview with: Amalie K. Kropp Lopez, MS MD Candidate Geisinger Commonwealth School of Medicine Class of 2023 Scranton, Pennsylvania MedicalResearch.com: What is the background for this study? Response: The opioid crisis is still affecting America, effecting millions of people from all walks of life. With the high risks of abuse and overtreatment with opioids, marijuana has been a newly reconsidered alterative for pain treatment. This study sought to quantify the changes in prescription opioid distribution using data reported by the Drug Enforcement Administration in Colorado after the legalization of recreational marijuana which gave the public increased access to its pain-relieving effects. (more…)
Author Interviews, Heart Disease, JAMA, Opiods, Surgical Research, University of Pennsylvania / 20.06.2020

MedicalResearch.com Interview with: Chase Brown, MD Associate Fellow, Leonard Davis Institute of Health Economics Integrated Cardiac Surgery Resident Hospital of the University of Pennsylvania Nimesh D. Desai, MD, PhD Director, Thoracic Aortic Surgery Research Program Associate Professor of Surgery Hospital of the University of Pennsylvania MedicalResearch.com: What is the background for this study? Dr. Chase Brown:  Opioid use in the United States is a public health emergency. We know that opioids prescribed after general surgery operations to patients who never received them within the year prior to their surgery are at increased risk for continuing to take opioids months later. However, this has not been studied in patients undergoing cardiac surgery, who often times have more severe post-operative pain. Our goal in this study was to determine how many patients after cardiac surgery and are opioid naive are continuing to take opioids within 90-180 days after their surgery.   (more…)